Glycosylation of monoclonal antibody products: Current status and future prospects
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Protein based therapeutics have started to dominate the pharmaceutical landscape primarily due to the high efficacy that they have demonstrated against complex diseases. Despite the significant success, issues with regards to safety, efficacy and quality of biotherapeutics have been a point of considerable debate and concern among the various stakeholders. The correlation between the glycoform profile and the safety and efficacy of a drug, in particular, has garnered significant attention of researchers worldwide. An escalated emphasis is presently given to develop an understanding of how the various process parameters as well molecular biology considerations contribute to glycan heterogeneity. This paper aims to review the major developments that have occurred in this area over the last decade. The impact of the various process parameters on glycan expression, methods for obtaining a pre‐determined glycan levels/profiles of a protein therapeutic and developments in the area of real‐time glycan monitoring and control are discussed. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1091–1102, 2016
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“expressed in Lec13 mutant have exhibited a 50-fold improvement in binding to FccRIIIa and a 100-fold increase in the ADCC activity.(14) Absence of core fucose leads to”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“Heterogeneity of antibody glycoforms imposes a significant challenge to the biopharmaceutical industry.(3) It is well accepted that conformation of an immunoglobulin (Ig) molecule is not just determined by its polypeptide sequence but also by multiple interactions that occur between polypeptide structure and carbohydr…”
BackgroundKim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801 · cited 2×
“The CHO cell line differs from the human cells with respect to the linkage between sialic acid and galactose as CHO cells lack the a2,6 sialyltransferase enzyme and generate only a-2,3-linked sialylated glycans whereas the humans cells exhibit both a2,3- & a-2,6-linked sialylated glycans with a preference for the latt…”
BackgroundFerrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 2×
“Another prominent difference is the absence of functional GnTIII enzyme which prevents the addition of bisecting GlcNAc residue.(18,33) Microheterogeneities introduced by the NS0 cells include addition of a-1,3-galactose epitope and Figure 3.”
BackgroundCell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00006-7 · Cited by 421
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · cited 2×
“The CDC activity has been found to be enhanced in the presence of galactose residue.(21) Removal of galactose residue after glycosidase treatment has been found to reduce complement lysis activity.”
BackgroundKanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · cited 2×
“Another prominent difference is the absence of functional GnTIII enzyme which prevents the addition of bisecting GlcNAc residue.(18,33) Microheterogeneities introduced by the NS0 cells include addition of a-1,3-galactose epitope and Figure 3.”
BackgroundBoyd, P. N., Lines, A. C., & Patel, A. K. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00118-2 · Cited by 283
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236 · cited 2×
“Significant loss of thermal stability has been observed upon removal of these residues together with a smaller decrease in binding affinity for soluble FccRIIb.(31) IgGs exhibit longer serum half-life with terminal GlcNAc residues.”
BackgroundImai-Nishiya (2007) · doi:10.1186/1472-6750-7-84 · Cited by 157
How does mild hypothermia affect monoclonal antibody glycosylation?
Sou, S. N., Sellick, C., Lee, K., Mason, A., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25524 · Cited by 107 · cited 1×
“More recently, better understanding of mAb production under hypothermic conditions has been established by studying the regulation of key glycan branching enzymes.(80) These enzymes have been found to be downregulated resulting in the formation of premature glycan structures in the final product.”
BackgroundJedrzejewski, P., Del Val, I., Constantinou, A., Dell, A., Haslam, S., Polizzi, K., & Kontoravdi, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034492 · Cited by 83
Fermentanomics: Monitoring Mammalian Cell Cultures with NMR Spectroscopy
Bradley, S. A., Ouyang, A., Purdie, J., Smitka, T. A., Wang, T., & Kaerner, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101962c · Cited by 80 · cited 2×
“This has propelled the emergence of neologisms such as fermentanomics involving real-time or near real-time monitoring of feed components and metabolites using 1D 1H NMR.75 Use of multivariate data analysis for assessing the relationship of mAb glycosylation with process variables and raw materials such as amino acids…”
MethodAghamohseni, H., Ohadi, K., Spearman, M., Krahn, N., Moo-Young, M., Scharer, J. M., Butler, M., & Budman, H. M. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.05.024 · Cited by 75 · cited 1×
“In a recent publication, the effect of glucose and glutamine on cell growth, mAb productivity and glycosylation levels were examined and glucose availability was found to play a crucial role in determining galactosylation and sialylation levels.(58) Depletion of glucose in intermittent periods of nutrient feeding duri…”
BackgroundHong, J. K., Lee, S. M., Kim, K.-Y., & Lee, G. M. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5596-8 · Cited by 46 · cited 1×
“Sodium butyrate has been known to enhance specific mAb productivity by arresting cell cycle phase, however, its addition to culture medium has been observed to reduce galactosylation level and increased basic charge heterogeneity in mAbs.(69) Addition of sodium butyrate has also been observed to reduce mAb sialylation…”
Background
Cited by
Capillary Electrophoresis Separations of Glycans
Lu, G., Crihfield, C. L., Gattu, S., Veltri, L. M., & Holland, L. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00669 · Cited by 174
Belov, A. M., Zang, L., Sebastiano, R., Santos, M. R., Bush, D. R., Karger, B. L., & Ivanov, A. R. (2018) · ELECTROPHORESIS · doi:10.1002/elps.201800067 · Cited by 88
Wang, C., Wang, J., Chen, M., Fan, L., Zhao, L., & Tan, W.-S. (2018) · Biotechnology Letters · doi:10.1007/s10529-018-2586-4 · Cited by 11
Bravo-Venegas, J., Rodriguez-Siza, J., Vergara, M., Torres, M., Dickson, A., Toledo, J. R., Molina, M. C., Hermoso, M. A., Berríos, J., & Altamirano, C. (2026) · mAbs · doi:10.1080/19420862.2026.2643039 · Cited by 6
“9,10 Factors such as the choice of the host cell line, cell culture conditions, and nutrient supply can significantly impact the glycosylation patterns.”
Metadata
- Authors
- Batra, J., & Rathore, A. S.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2016-09
- Volume
- 32
- Issue
- 5
- Pages
- 1091-1102
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2526872992
- Cited by
- 63
- References
- 23
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.